Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril et al. · Diabetes Care · 2020
OBJECTIVE: Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: : 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics and unaware of having NAFLD were recruited. At the visit, volunteers were invited to be screened by elastography for steatosis and fibrosis by controlled attenuation parameter (≥274 dB/m) and liver stiffness measurement (LSM; ≥7.0 kPa), respectively. Secondary causes of liver disease were ruled out. Diagnostic panels for prediction of advanced fibrosis, such as AST-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) index, were also measured. A liver biopsy was performed if results were suggestive of fibrosis. RESULTS: The prevalence of steatosis was 70% and of fibrosis 21% (LSM ≥7.0 kPa). Moderate fibrosis (F2: LSM ≥8.2 kPa) was present in 6% and severe fibrosis or cirrhosis (F3-4: LSM ≥9.7 kPa) in 9%, similar to that estimated by FIB-4 and APRI panels. Noninvasive testing was consistent with liver biopsy results. Elevated AST or ALT ≥40 units/L was present in a minority of patients with steatosis (8% and 13%, respectively) or with liver fibrosis (18% and 28%, respectively). This suggests that AST/ALT alone are insufficient as initial screening. However, performance may be enhanced by imaging (e.g., transient elastography) and plasma diagnostic panels (e.g., FIB-4 and APRI). CONCLUSIONS: Moderate-to-advanced fibrosis (F2 or higher), an established risk factor for cirrhosis and overall mortality, affects at least one out of six (15%) patients with T2DM. These results support the American Diabetes Association guidelines to screen for clinically significant fibrosis in patients with T2DM with steatosis or elevated ALT.
Cited by 351 works. doi:10.2337/dc20-1997
Authors
- Romina Lomonaco
- Eddison Godinez Leiva
- Fernando Bril
- Sulav Shrestha
- LYDIA MANSOUR
- Jeff Budd
- Jessica Portillo Romero
- Siegfried O. Schmidt
- Ku-Lang Chang
- George P. N. Samraj
- John Z. Malaty
- Katherine Huber
- Pierre Bédossa
- Srilaxmi Kalavalapalli
- JONATHAN S. MARTE
- Diana Barb
- Danielle Poulton
- Nada Fanous
- Kenneth J. Cusi
References
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- Mechanisms of NAFLD development and therapeutic strategies
- The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
- Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease